aTyr Pharma: Good Safety Data In Pulmonary Sarcoidosis, Institutions Are AccumulatingBy mariocazombo76@gmail.com / March 14, 2025
Ideal Power: Revenue Ramp And Stellantis Phase 3 Around The Corner February 28, 2025 / IPWR, Tejo Strategy Investing / By mariocazombo76@gmail.com
NewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of Obicetrapib March 1, 2025 / NAMS, Tejo Strategy Investing / By mariocazombo76@gmail.com
By
/ March 14, 2025 By
/ March 14, 2025 By
/ March 14, 2025 By
/ March 14, 2025 By
/ March 14, 2025 By
/ March 14, 2025